Seres Therapeutics, Inc. (MCRB) income statement
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.33−0.11 (-7.64%)
Close on Nov 19, 2026Market cap $13.22MP/E –Yield –
Seres Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -4462.8%
- Net margin
- -1192.9%
- Return on equity, FY2025
- 19.6%
Financial strength
- Current ratio
- 2.11
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 77.8%
Valuation
- P/E ratio
- –
- Price to sales
- 7.02
- Price to book
- 0.38
- Dividend yield
- –
See a number that looks wrong?